Characterization and Diagnostic Work-up of a Patient with Functionally Impaired Platelet GP6
Verena Klümpers
1
Institute of Transfusion Medicine and Immunology, Heidelberg University, Medical Faculty Mannheim, German Red Cross Blood Service Baden-Württemberg – Hessen, Mannheim Germany
,
Isabelle Müller
2
Institute of Clinical Hemostaseology and Transfusion Medicine, Saarland University and Saarland University Medical Center, 66421 Homburg, Germany
,
Peter Hellstern
3
Center of Hemostasis and Thrombosis, Zurich, Switzerland
,
Torsten J. Schulze
1
Institute of Transfusion Medicine and Immunology, Heidelberg University, Medical Faculty Mannheim, German Red Cross Blood Service Baden-Württemberg – Hessen, Mannheim Germany
,
Christine Mannhalter
4
Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
,
Peter Bugert
1
Institute of Transfusion Medicine and Immunology, Heidelberg University, Medical Faculty Mannheim, German Red Cross Blood Service Baden-Württemberg – Hessen, Mannheim Germany
,
Hermann Eichler
2
Institute of Clinical Hemostaseology and Transfusion Medicine, Saarland University and Saarland University Medical Center, 66421 Homburg, Germany
Platelet function assays are commonly used diagnostic tools in patients with suspected inherited or acquired hemostatic disorders, and to monitor the efficacy of anti-platelet medication.[1]
[2] Beside different newer point-of-care assays, such as the platelet function analyzer (PFA) or the whole blood aggregometry (WBA),[3]
[4] the classical Born's light transmission platelet aggregometry (LTA) is an indispensable diagnostic tool for hemostaseologists and therefore still frequently performed in specially equipped laboratories.[5] For routine testing of platelet function by the LTA assay, the patient's platelet rich plasma (PRP) is mixed with different platelet activating agonists, such as ristocetin, ADP, collagen, and arachidonic acid.[5] In few patients, testing their PRP by the LTA assay leads to an isolated missing response in the collagen-induced aggregation, while the platelets respond normally to all the other agonists.[6]
[7]
[8] Regarding the collagen-induced aggregation, the platelet membrane glycoprotein VI (GP6) plays a central role.[9]
[10] It is expressed as a complex with the Fc receptor γ-chain (FcRγ) and has been identified as the main physiological platelet receptor for collagen.[11] When collagen binds to GP6, an activation cascade is initiated by tyrosine phosphorylation inducing the formation of a complex of signal-transducing proteins.[11] The collagen/GP6 interaction finally leads to a physiologic activation of platelets, which can be measured in vitro by the formation of platelet aggregates from PRP. On the other hand, in patients with bleeding tendency displaying a negative collagen reaction in the LTA assay but positive results for all other agonists including arachidonic acid, an acquired or inherited functional defect of GP6 could be the possible cause of the bleeding disorder.[12]
[13]
[14]
[15]
[16]
In this case report of a female patient suffering from a clinically mild bleeding disorder, we describe the complexity of the respective diagnostic work-up to elucidate a suspected functional GP6 defect.
References
1
Harrison P.
Platelet function analysis. Blood Rev 2005; 19: 111-123
4
Toth O,
Calatzis A,
Penz S.
, et al. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 2006; 96: 781-788
6
Bellucci S,
Huisse MG,
Boval B.
, et al. Defective collagen-induced platelet activation in two patients with malignant haemopathies is related to a defect in the GPVI-coupled signalling pathway. Thromb Haemost 2005; 93: 130-138
8
Moroi M,
Jung SM,
Okuma M.
, et al. A patient with platelets deficient in glycoprotein VI that lack both collagen-induced aggregation and adhesion. J Clin Invest 1989; 84: 1440-1445
9
Gibbins JM,
Okuma M,
Farndale R.
, et al. Glycoprotein VI is the collagen receptor in platelets which underlies tyrosine phosphorylation of the Fc receptor gamma-chain. FEBS letters 1997; 413: 255-259
10
Jandrot-Perrus M,
Busfield S,
Lagrue AH.
, et al. Cloning, characterization, and functional studies of human and mouse glycoprotein VI: a platelet-specific collagen receptor from the immunoglobulin superfamily. Blood 2000; 96: 1798-1807
12
Dunkley S,
Arthur JF,
Evans S.
, et al. A familial platelet function disorder associated with abnormal signalling through the glycoprotein VI pathway. Br J Haematol 2007; 137: 569-577
14
Hermans C,
Wittevrongel C,
Thys C.
, et al. A compound heterozygous mutation in glycoprotein VI in a patient with a bleeding disorder. J Thromb Haemost 2009; 7: 1356-1363
15
Kojima H,
Moroi M,
Jung SM.
, et al. Characterization of a patient with glycoprotein (GP) VI deficiency possessing neither anti-GPVI autoantibody nor genetic aberration. J Thromb Haemost 2006; 4: 2433-2442
16
Nurden P,
Tandon N,
Takizawa H.
, et al. An acquired inhibitor to the GPVI platelet collagen receptor in a patient with lupus nephritis. J Thromb Haemost 2009; 7: 1541-1549
17
Jandrot-Perrus M,
Lagrue AH,
Leduc M.
, et al. Convulxin-induced platelet adhesion and aggregation: involvement of glycoproteins VI and Ia/IIa. Platelets 1998; 9: 207-211
19
Hagenstrom H,
Schlenke P,
Hennig H.
, et al. Quantification of platelet-associated IgG for differential diagnosis of patients with thrombocytopenia. Thromb Haemost 2000; 84: 779-783
20
Kiefel V,
Santoso S,
Weisheit M.
, et al. Monoclonal antibody--specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies. Blood 1987; 70: 1722-1726
22
Bugert P,
Lese A,
Meckies J.
, et al. Optimized sensitivity of allele-specific PCR for prenatal typing of human platelet alloantigen single nucleotide polymorphisms. Biotechniques 2003; 35: 170-174
23
Rolf N,
Knoefler R,
Suttorp M.
, et al. Optimized procedure for platelet RNA profiling from blood samples with limited platelet numbers. Clin Chem 2005; 51: 1078-1080
26
Matus V,
Valenzuela G,
Saez CG.
, et al. An adenine insertion in exon 6 of human GP6 generates a truncated protein associated with a bleeding disorder in four Chilean families. J Thromb Haemost 2013; 11: 1751-1759
27
Watkins NA,
O‘Connor MN,
Rankin A.
, et al. Definition of novel GP6 polymorphisms and major difference in haplotype frequencies between populations by a combination of in-depth exon resequencing and genotyping with tag single nucleotide polymorphisms. J Thromb Haemost 2006; 4: 1197-1205
28
Marjoram RJ,
Li Z,
He L.
, et al. alpha2beta1 integrin, GPVI receptor, and common FcRgamma chain on mouse platelets mediate distinct responses to collagen in models of thrombosis. PloS one 2014; 9: e114035
29
Gratacap MP,
Martin V,
Valera MC.
, et al. The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. Blood 2009; 114: 1884-1892
30
Watson CN,
Kerrigan SW,
Cox D.
, et al. Human platelet activation by Escherichia coli: roles for FcγRIIA and integrin αIIbβ3. Platelets 2016; 27: 535-540
31
Ungerer M,
Rosport K,
Bultmann A.
, et al. Novel antiplatelet drug revacept (Dimeric Glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans. Circulation 2011; 123: 1891-1899